Close
Almac
Achema middle east

Upsher-Smith launches new prenatal vitamin

Note* - All images used are for editorial and illustrative purposes only and may not originate from the original news provider or associated company.

Subscribe

- Never miss a story with notifications

- Gain full access to our premium content

- Browse free from any location or device.

Media Packs

Expand Your Reach With Our Customized Solutions Empowering Your Campaigns To Maximize Your Reach & Drive Real Results!

– Access the Media Pack Now

– Book a Conference Call

– Leave Message for Us to Get Back

Related stories

First GLP-1 Pill for Obesity by Novo Nordisk Approved by FDA

The U.S. Food and Drug Administration – FDA on...

How High-Achievers Stay Future-Ready in Evolving Job Markets

Job markets today are transforming rapidly. In the past...

Proactive Risk Management as a Core Capability in Pharma Development

Risk management in pharma is often treated as a reactive compliance box-ticking exercise. This article argues for reframing risk as a strategic competitive advantage. It details proactive frameworks like the "Excipient Exclusion Filter," Decision Quality (DQ) matrices, and "pre-mortem" analyses that allow development teams to anticipate failure modes and engineer them out of the pipeline before they occur.
- Advertisement -

Upsher-Smith Laboratories has launched B-Nexa, a prescription prenatal vitamin for pregnant women who suffer from nausea and vomiting of pregnancy (NVP).

B-Nexa is designed with B vitamins and ginger to help calm NVP, also known as morning sickness, the most common symptom of pregnancy, the company said. Taken once or twice daily, B-Nexa contains vitamin B6 and ginger to help calm nausea and vomiting during pregnancy. Each antihistamine-free tablet also contains 1.2mg folic acid.

Upsher-Smith medical affairs senior director Wesley Todd said that B-Nexa is a new option in the prenatal nutrition market that has been designed to help calm nausea and vomiting of pregnancy.

Latest stories

Related stories

First GLP-1 Pill for Obesity by Novo Nordisk Approved by FDA

The U.S. Food and Drug Administration – FDA on...

How High-Achievers Stay Future-Ready in Evolving Job Markets

Job markets today are transforming rapidly. In the past...

Proactive Risk Management as a Core Capability in Pharma Development

Risk management in pharma is often treated as a reactive compliance box-ticking exercise. This article argues for reframing risk as a strategic competitive advantage. It details proactive frameworks like the "Excipient Exclusion Filter," Decision Quality (DQ) matrices, and "pre-mortem" analyses that allow development teams to anticipate failure modes and engineer them out of the pipeline before they occur.

Rethinking Pipeline Value Beyond Peak Sales Forecasts

The traditional reliance on risk-adjusted Net Present Value (rNPV) and peak sales forecasts is failing to capture the true potential of modern pharmaceutical assets, particularly platform technologies. This article introduces holistic valuation frameworks like Real Options Analysis (ROA) and the Platform VISTA model, arguing for a shift toward valuing "strategic fit," "lifecycle potential," and the intangible equity of innovation engines.

Subscribe

- Never miss a story with notifications

- Gain full access to our premium content

- Browse free from any location or device.

Media Packs

Expand Your Reach With Our Customized Solutions Empowering Your Campaigns To Maximize Your Reach & Drive Real Results!

– Access theMedia Pack Now

– Book a Conference Call

– Leave Message for Us to Get Back

Translate »